D. E. Shaw & Co. Inc. Sells 27,030 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

D. E. Shaw & Co. Inc. lessened its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 12.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 197,107 shares of the biotechnology company's stock after selling 27,030 shares during the period. D. E. Shaw & Co. Inc. owned 0.65% of AnaptysBio worth $2,610,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ANAB. Tower Research Capital LLC TRC raised its stake in AnaptysBio by 131.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after buying an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in AnaptysBio in the fourth quarter valued at $40,000. AlphaQuest LLC increased its stake in AnaptysBio by 1,891.5% in the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 4,237 shares in the last quarter. Virtus ETF Advisers LLC increased its stake in AnaptysBio by 24.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock valued at $63,000 after purchasing an additional 936 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in AnaptysBio by 1,585.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock valued at $75,000 after purchasing an additional 5,360 shares in the last quarter.

Wall Street Analysts Forecast Growth

ANAB has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Wolfe Research initiated coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price target for the company. Guggenheim lifted their price target on shares of AnaptysBio from $52.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Wedbush reaffirmed an "outperform" rating and issued a $40.00 price target on shares of AnaptysBio in a research note on Thursday, May 1st. Finally, Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $35.88.

AnaptysBio Stock Performance

AnaptysBio stock opened at $20.47 on Tuesday. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $41.31. The stock has a market cap of $601.41 million, a PE ratio of -3.37 and a beta of -0.20. The firm's 50-day simple moving average is $19.03 and its 200 day simple moving average is $18.23.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.30) by $0.02. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $27.77 million for the quarter, compared to analysts' expectations of $15.27 million. As a group, analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has authorized a stock repurchase program on Monday, March 24th that permits the company to buyback $75.00 million in outstanding shares. This buyback authorization permits the biotechnology company to purchase up to 13.1% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's board believes its shares are undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.